

06 Feb 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: will 2022 herald more big M&A deals?; Novartis's four R&D philosophies; new clinical holds at Gilead; Pfizer recruits new chief development officer from Roche; and *Scrip* asks what this year will bring in the markets, competition and business strategy areas.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 4 February 2022, including: will 2022 herald more big M&A deals?; [Novartis AG](#)'s four R&D philosophies; new clinical holds at [Gilead Sciences, Inc.](#); [Pfizer Inc.](#) recruits new chief development officer from [Roche Holding AG](#); and *Scrip* asks what this year will bring in the markets, competition and business strategy areas.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[A Biopharma M&A Bonanza In 2022? Analysts Pick Top Targets And Likely Buyers](#)" - Scrip, 2 Feb, 2022.)

(Also see "[Novartis's John Tsai On The Four Philosophies Driving R&D](#)" - Scrip, 31 Jan, 2022.)

(Also see "[Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds](#)" - Scrip, 1 Feb, 2022.)

(Also see "[Pfizer Recruits Chief Development Officer William Pao From Roche R&D Team](#)" - Scrip, 1

Feb, 2022.)

(Also see "[*Scrip Asks...What Does 2022 Hold For Biopharma? Part 1: Markets, Competition And Business Strategy*](#)" - Scrip, 1 Feb, 2022.)

[*Click here to explore this interactive content online*](#) 